Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT06012435 2026-03-18

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

703 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT06524544 2026-03-18

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT04928846 2026-03-16

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

698 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06038539 2026-03-13

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Phase 3 Terminated

55 enrolled

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

NCT06925737 2026-03-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT06952504 2026-03-13

TroFuse-033

1,123 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07225946 2026-03-13

KLK2-PASenger

800 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06635824 2026-03-12

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

191 enrolled

Lung Neoplasms

NCT06881784 2026-03-12

RASolve 301

420 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06989112 2026-03-12

DE-01

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT07463573 2026-03-11

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

466 enrolled

Esophageal Squamous Cell Carcinoma

NCT07464327 2026-03-11

A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

450 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03221426 2026-03-09

KEYNOTE-585

Phase 3 Completed

1,007 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06346392 2026-03-09

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

572 enrolled

Stomach Neoplasms

NCT06472245 2026-03-06

ARTEMIA

363 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06551324 2026-03-04

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT06931340 2026-03-04

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

1,260 enrolled

Prostatic Neoplasms

NCT07442565 2026-03-04

SYNSTAR03

506 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

403 enrolled 10 charts

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT05538663 2026-03-02

BRIDGE

870 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07441460 2026-03-02

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

1,800 enrolled

Resectable HER2-positive Breast Cancer

NCT03574571 2026-02-27

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

732 enrolled

Prostatic Neoplasms

NCT06356311 2026-02-27

TroFuse-015

450 enrolled

Adenocarcinoma Of Esophagus

NCT07435324 2026-02-27

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

161 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07377643 2026-02-25

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

540 enrolled

HER2-positive Breast Cancer

NCT07432178 2026-02-25

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

2,288 enrolled

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3 Completed

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT07419295 2026-02-19

TroFuse-031

590 enrolled

Urinary Bladder Neoplasms

NCT05378763 2026-02-18

PINNACLE

Phase 3 Suspended

268 enrolled

NSCLC

NCT07416994 2026-02-18

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

440 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06439225 2026-02-11

OPTION-DDR

236 enrolled

Prostatic Neoplasms

NCT07291037 2026-02-10

TROPION-Lung17

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04656652 2026-02-05

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

605 enrolled 14 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT07386938 2026-02-04

A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

246 enrolled

Breast Neoplasms

NCT03390504 2026-02-02

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT06340568 2026-02-02

Fern-EC-01

480 enrolled

Endometrial Neoplasms

NCT07196774 2026-01-30

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

740 enrolled

Early-stage or Locally Advanced HER2-positive Breast Cancer

NCT06764485 2026-01-28

rechARge

960 enrolled

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07371897 2026-01-28

SHINE

154 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07365995 2026-01-26

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

387 enrolled

Neoplasms, Stomach Neoplasms

NCT06976190 2026-01-20

Magic-C002

446 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT05296798 2026-01-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

922 enrolled

Breast Neoplasms

NCT03801876 2026-01-14

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

300 enrolled

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT06592924 2026-01-14

TRIPLE-SWITCH

830 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT06644781 2026-01-12

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

510 enrolled